NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free IMRX Stock Alerts $2.89 +0.46 (+18.93%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.40▼$2.9750-Day Range$1.91▼$6.7652-Week Range$1.90▼$14.29Volume951,900 shsAverage Volume561,239 shsMarket Capitalization$84.62 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Immuneering alerts: Email Address Immuneering MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside436.3% Upside$15.50 Price TargetShort InterestBearish12.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.26Based on 10 Articles This WeekInsider TradingSelling Shares$1.89 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.38 out of 5 starsMedical Sector139th out of 938 stocksPharmaceutical Preparations Industry54th out of 420 stocks 4.3 Analyst's Opinion Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Immuneering has a forecasted upside of 436.3% from its current price of $2.89.Amount of Analyst CoverageImmuneering has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.41% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Immuneering has recently decreased by 2.61%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMRX. Previous Next 4.0 News and Social Media Coverage News SentimentImmuneering has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Immuneering this week, compared to 2 articles on an average week.Search Interest21 people have searched for IMRX on MarketBeat in the last 30 days. MarketBeat Follows13 people have added Immuneering to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have sold 610.24% more of their company's stock than they have bought. Specifically, they have bought $266,645.00 in company stock and sold $1,893,819.00 in company stock.Percentage Held by Insiders23.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($1.89) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Immuneering Stock (NASDAQ:IMRX)Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More IMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMRX Stock News HeadlinesMarch 26, 2024 | insidertrades.com3 Stocks Insiders Are Buying That Analysts LoveMarch 26, 2024 | insidertrades.comImmuneering Co. (NASDAQ:IMRX) Insider Harold Eugene Brakewood Buys 3,900 SharesMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 26, 2024 | insidertrades.comInsider Buying: Immuneering Co. (NASDAQ:IMRX) Director Acquires 25,000 Shares of StockMarch 22, 2024 | insidertrades.comInsider Buying: Immuneering Co. (NASDAQ:IMRX) Insider Acquires 3,818 Shares of StockMarch 20, 2024 | insidertrades.comImmuneering Co. (NASDAQ:IMRX) CEO Purchases $55,400.00 in StockMarch 19, 2024 | insidertrades.comCormorant Asset Management, Lp Sells 509,091 Shares of Immuneering Co. (NASDAQ:IMRX) StockMarch 27, 2024 | globenewswire.comImmuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | investing.comImmuneering CEO acquires $55.3k in company stockMarch 21, 2024 | finance.yahoo.comImmuneering Director Acquires 7.5% More StockMarch 19, 2024 | americanbankingnews.comImmuneering Co. (NASDAQ:IMRX) Major Shareholder Cormorant Asset Management, Lp Sells 509,091 SharesMarch 19, 2024 | americanbankingnews.comChardan Capital Lowers Immuneering (NASDAQ:IMRX) Price Target to $16.00March 18, 2024 | msn.comImmuneering stock rebounds 34% following last week's selloffMarch 18, 2024 | benzinga.comWhy Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 18, 2024 | msn.comCanopy Growth, Outlook Therapeutics, Immuneering among healthcare moversMarch 15, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.49%March 15, 2024 | markets.businessinsider.comImmuneering: Hold Rating Amidst Potential and Uncertainties in Drug EfficacyMarch 15, 2024 | markets.businessinsider.comCancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial DataMarch 14, 2024 | benzinga.comWhy Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 14, 2024 | msn.comWhat's Going On With Cancer-Focused Immuneering Stock On Thursday?March 14, 2024 | markets.businessinsider.comImmuneering IMM-1-104 Trial In RAS-Mutant Solid Tumors Shows Positive Results; Stock UpMarch 14, 2024 | globenewswire.comImmuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsMarch 13, 2024 | finanznachrichten.deImmuneering Corporation: Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsMarch 12, 2024 | finance.yahoo.comImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsMarch 12, 2024 | globenewswire.comImmuneering Appoints Thomas J. Schall, Ph.D.March 11, 2024 | markets.businessinsider.comImmuneering’s IMM-1-104 Progress Garners Buy Rating Amid Favorable Phase 2 Dose Determination and Anticipated Phase 1 DataSee More Headlines Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRX CUSIPN/A CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$25.00 Low Stock Price Target$3.00 Potential Upside/Downside+436.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,470,000.00 Net MarginsN/A Pretax Margin-5,163,499.50% Return on Equity-52.49% Return on Assets-47.63% Debt Debt-to-Equity RatioN/A Current Ratio11.35 Quick Ratio11.35 Sales & Book Value Annual Sales$320,000.00 Price / Sales264.44 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book0.94Miscellaneous Outstanding Shares29,280,000Free Float22,548,000Market Cap$84.62 million OptionableNot Optionable Beta-0.75 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Benjamin J. Zeskind M.B.A. (Age 42)Ph.D., Co-Founder, President, CEO & Director Comp: $898.42kMr. Robert J. Carpenter M.B.A. (Age 78)M.S., Co-Founder & Chair Emeritus Comp: $83.17kDr. Brett M. Hall Ph.D. (Age 56)Chief Scientific Officer Comp: $867.92kMs. Mallory Morales CPA (Age 40)Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate ControllerMr. Michael D. Bookman J.D. (Age 36)Chief Legal Officer & Secretary Ms. Leah R. Neufeld (Age 52)Chief People Officer Dr. Peter King Ph.D.Head of Discovery & VPDr. Praveen Nair Ph.D.Head of Translational Pharmacology & VPMr. Harold E. Brakewood (Age 59)Chief Business Officer More ExecutivesKey CompetitorsvTv TherapeuticsNASDAQ:VTVTKronos BioNASDAQ:KRONAssembly BiosciencesNASDAQ:ASMBJourney MedicalNASDAQ:DERMEquilliumNASDAQ:EQView All CompetitorsInsiders & InstitutionsPeter FeinbergBought 25,000 shares on 3/22/2024Total: $63,750.00 ($2.55/share)Harold Eugene BrakewoodBought 3,900 shares on 3/22/2024Total: $10,023.00 ($2.57/share)Mallory MoralesBought 1,107 shares on 3/21/2024Total: $3,011.04 ($2.72/share)Leah R NeufeldBought 3,818 shares on 3/20/2024Total: $10,995.84 ($2.88/share)Benjamin J ZeskindBought 20,000 shares on 3/19/2024Total: $55,400.00 ($2.77/share)View All Insider TransactionsView All Institutional Transactions IMRX Stock Analysis - Frequently Asked Questions Should I buy or sell Immuneering stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMRX shares. View IMRX analyst ratings or view top-rated stocks. What is Immuneering's stock price target for 2024? 8 Wall Street analysts have issued 1 year target prices for Immuneering's shares. Their IMRX share price targets range from $3.00 to $25.00. On average, they predict the company's share price to reach $15.50 in the next year. This suggests a possible upside of 436.3% from the stock's current price. View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts. How have IMRX shares performed in 2024? Immuneering's stock was trading at $7.35 at the beginning of 2024. Since then, IMRX shares have decreased by 60.7% and is now trading at $2.89. View the best growth stocks for 2024 here. When is Immuneering's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our IMRX earnings forecast. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) announced its quarterly earnings results on Friday, March, 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.06. What ETF holds Immuneering's stock? Range Cancer Therapeutics ETF holds 13,232 shares of IMRX stock, representing 1.36% of its portfolio. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Immuneering's major shareholders? Immuneering's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.54%), Price T Rowe Associates Inc. MD (11.54%), Citadel Advisors LLC (7.10%), Vanguard Group Inc. (3.67%), Vanguard Group Inc. (3.67%) and Goldman Sachs Group Inc. (1.56%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Cormorant Asset Management, Lp, Harold Eugene Brakewood, Laurie Keating, Leah R Neufeld, Mallory Morales, Michael Bookman, Peter Feinberg and Scott Barrett. View institutional ownership trends. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.